|
KMID : 0620920020340020145
|
|
Experimental & Molecular Medicine
2002 Volume.34 No. 2 p.145 ~ p.151
|
|
|
Inhibitory action of bisphosphonates on bone resorption does not involve the regulation of RANKL and OPG expression
|
|
Jeong Hwa Baek/Young Hee Kim
Gwan Shik Kim/Jeong Hwa Baek
|
|
|
Abstract
|
|
|
|
The mechanism of inhibitory action of bisphosphonates on bone resorption is not fully elucidated. Osteoclast formation and activity are regulated by osteoblast-derived factors such as the osteoclast differentiating factor, receptor activator of NF-κB ligand (RANKL) and the inhibitor, osteoprotegerin (OPG). To investigate in vitro effects of bisphosphonates on mouse osteoblastic cells, we examined the expression levels of RANKL and OPG in the cells treated with alendronate or pamidronate (10(-8) ∼10(-5)M) alone, or combined with 10 nM of 1,25-(OH)2VitD3 for 24 or 48 h. Various concentrations of alendronate and pamidronate did not change the mRNA expression of RANKL and OPG consistently irrespective of 1,25-(OH)2VitD3 presence. When added into cocultures of mouse osteoblastic cells and bone marrow cells, both alendronate and pamidronate inhibited osteoclast formation and bone resorption but failed to alter the RANKL and OPG mRNA expression. These results indicate that the inhibition of bone resorption by bisphosphonates is not mediated by the regulation of RANKL and OPG expression.
|
|
|
KEYWORD
|
|
|
RANKL, OPG, alendronate, pamidronate, osteoclastogenesis,
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
    
|